The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study
Open accessAbstract
CONTEXT: In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation. OBJECTIVE: The study was performed to confirm the correlation of the currently used mitotane (o,p'DDD) threshold of 14 mg/liter with tumor response and to evaluate the additional value of 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p'DDA) and o,p'DDE (1,1-(o,p'-dichlorodiphenyl)-2,2 dichloroethene) levels for predicting tumor response. SUBJECTS/METHODS: Plasma samples collected within 3 months of best response from 91 patients on mitotane therapy for advanced ACC were analyzed retrospectively. O,p'DDD and metabolites were assessed and related to tumor response and survival. Receiver operating characteristic curves were used. Sensitivity and specificity were calculated for different cutoff levels of o,p'DDD and metabolites. RESULTS: Objective tumor response was observed in 19% of patients. Median o,p'DDD level was higher in responders (P = 0.03). More responders were found among patients achieving o,p'DDD levels 14 mg/liter or greater (P = 0.02). Univariate and multivariate analysis showed significantly longer survival for patients with o,p'DDD levels 14 mg/liter or greater (hazard ratio 0.52, P = 0.04, hazard ratio 0.46, P = 0.03). An o,p'DDD cutoff value of 14 mg/liter was associated with a sensitivity of 65% and specificity 69%. An o,p'DDD level 20 mg/liter or greater or 14 mg/liter or greater combined with o,p'DDA level 92 mg/liter or greater was associated with a specificity of 90 and 92%, respectively. CONCLUSIONS: Our data confirm the value of o,p'DDD plasma monitoring as well as targeting the 14 mg/liter cutoff level in the therapeutic management of ACC patients. Furthermore, our results suggest additional benefit of higher levels of o,p'DDD and combined measurement of o,p'DDD and o,p'DDA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most studies, including a large retrospective analysis, have defined the therapeutic mitotane level to be 14 to 20 mg/L (296).”
From Adrenocortical carcinoma (2014) · cites this paper as [296]
In the citing paper
“Similarly, in Europe, a recent analysis of the Dutch Adrenal Network Registry found that radiotherapy is employed in only 8% of patients (296).”
From Adrenocortical carcinoma (2014) · cites this paper as [296]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
Haak, H. R., Hermans, J., van de Velde, C., Lentjes, E. G. W. M., Goslings, B. M., Fleuren, G. J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Self-citationHutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271
Crucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P. (1996) · Surgery · doi:10.1016/s0039-6060(96)80164-4 · Cited by 247
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Self-citationCHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD
Bergenstal, D. M., Hertz, R., Lipsett, M. B., & Moy, R. H. (1960) · Annals of Internal Medicine · doi:10.7326/0003-4819-53-4-672 · Cited by 230
Cited by
Sorted by citations
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Self-citationUpdate in Adrenocortical Carcinoma
Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Self-citationFaßnacht, M., Berruti, A., Baudin, É., Demeure, M. J., Gilbert, J., Haak, H. R., Kroiß, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 342
Self-citation
Metadata
- Authors
- Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., Allolio, B., Haak, H. R., & Baudin, E.
- Affiliations
- Máxima Medisch Centrum (NL)
- University of Würzburg (DE)
- University of Turin (IT)
- Institut Gustave Roussy (FR)
- Corresponding author
- Hermsen, Ilse G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1844-1851
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1995124360
- Cited by
- 173
- References
- 36
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 8 · 2016: 15 · 2015: 13 · 2014: 17 · 2013: 14 · 2012: 18
- FWCI
- 17.99
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, mitotane, o,p'-DDE, plasma drug concentration, therapeutic drug monitoring, tumor response prediction, survival, dose-response relationship, cut-off values, predictive biomarkers
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mitotane, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
